- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02320123
End-of-Life Care for African Americans
End-of-Life Care for African Americans: Intervention Design and Implementation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim 1:
A. We will conduct semi-structured interviews with patient/caregiver pairs and focus groups with providers that will test the communication strategies of available audiovisual materials and materials that we will develop for the intervention. The audiovisual segments will be taken from an available EOL care educational digital versatile disc (DVD). We aim to interview 12 patients and their caregivers, or more until thematic saturation is reached. We will obtain informed consent, and all interviews will be audiotaped and transcribed. Interviews will be conducted separately, and will last 30 to 45 minutes.
B. Two focus groups will be conducted with palliative care providers to identify communication strategies they use with AAs. One will be conducted with providers from Parkland Hospital. The other will be conducted with providers from University Hospitals, the Dallas VA, and Baylor University Medical Center in Dallas. Informed consent will be obtained. All sessions will be audiotaped and transcribed. The focus groups will last 45 to 60 minutes.
C. We will create additional DVD segments that will address previously identified barriers to EOL care for AAs, including: 1) spiritual/religious conflict, and 2) medical mistrust. We will obtain feedback on the newly developed segments from 10 new patient/caregiver dyads (semi-structured interviews) and 6 to 8 AA religious leaders (focus group) recruited from local churches. Informed consent will be obtained prior to conducting the interviews and focus groups. All will last 30 to 60 minutes.
D. A lay health advisor (LHA) will be recruited from the community to provide counsel about EOL care to patients who will receive the intervention. The LHA and the PI of the project will undergo training in how to provide culturally sensitive EOL care for AAs via the APPEAL (A Progressive Palliative Care Educational Curriculum for the Care of AAs at Life's End) Curriculum created at Duke University. After training, the LHA will participate in in-service work with the Parkland Palliative Care Team and the PI.
Aim 2:
We will use an e-EOL algorithm to identify AA patients hospitalized at Parkland who have advanced breast, lung, and colorectal cancer to identify potentially eligible candidates for the intervention utilizing EMR data from Parkland Hospital (See Aim 1 eligibility criteria). Once eligibility is confirmed the LHA will introduce the study to the patient and obtain informed consent. Each patient will be asked to identify a primary caregiver that will be able to participate in the intervention. The LHA will contact the patients' primary caregivers to confirm participation in the study and arrange a time to meet with both the patient and caregiver to conduct the intervention. We anticipate that 24 patient-caregiver pairs will receive the intervention (8 for each type of cancer).
The LHA will meet with eligible patients and caregivers and assist them in watching the developed DVD segments. Afterward, the LHA will answer questions and provide additional information. They will tailor the discussion to the patient's values, preferences, concerns, and clinical circumstances.
The primary process outcome tested will be the feasibility and acceptability of the intervention. Feasibility success will be measured by the number and rates of patients/caregivers who complete the intervention and follow-up interviews. The primary decision-making outcome is change in intent to discuss EOL care options based on the Transtheoretical Stages of Change Model (i.e., pre-contemplation, contemplation, preparation, and action). Secondary outcomes measured will include: knowledge of prognosis and EOL care options, decisional conflict, quality of life, and health care utilization. Other patient and treatment variables will also be collected, per the study protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Parkland Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Aim 1 patients must:
- receive their care at Parkland and be diagnosed with advanced cancer (breast, lung, or colon);
- self-identify as AA;
- be proficient in English;
- be competent to give informed consent; and
- have no evidence of cognitive impairment (Mini-Cog score of ≥3 or 1-2 with normal clock draw).
Aim 2 Patients must:
- be hospitalized at Parkland
- be diagnosed with advanced cancer (breast, lung, or colon)
- self-identify as AA;
- be proficient in English;
- be competent to give informed consent;
- have no evidence of cognitive impairment (Mini-Cog score of ≥3 or 1-2 with normal clock draw); and
- have never received palliative or hospice care.
All Caregivers (Aim 1 and 2) must be:
- identified by the selected patients as their primary caregiver;
- be 21 years of age or older;
- proficient in English; and
- competent to give informed consent.
For the expert provider focus group, participants must be a health care provider (physician, nurse practitioner, chaplain, social worker, nurse) who works within hospice and palliative medicine.
(Note: patients who enter palliative care or hospice during follow-up interviews will be allowed to remain in the study)
Exclusion Criteria:
For patients:
- identify with a race other than African American or
- have a diagnosis other than advanced breast, lung, or colorectal cancer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patients - intervention
For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
|
African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
|
|
No Intervention: Patients - Control
Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intent to Discuss Advance Directives (Based on the Transtheoretical Stages of Change Model)
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The primary decision-making outcome is change in intent to discuss advance directives based on the Transtheoretical Stages of Change Model (i.e., pre-contemplation, contemplation, preparation, action, and maintenance).
|
Within six months after patient enrolls in study, June 2017.
|
|
Intent to Discuss Medical Power of Attorney (Based on the Transtheoretical Stages of Change Model)
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The primary decision-making outcome is change in intent to discuss medical power of attorney based on the Transtheoretical Stages of Change Model (i.e., pre-contemplation, contemplation, preparation, action, and maintenance).
|
Within six months after patient enrolls in study, June 2017.
|
|
Intent to Discuss Palliative Care (Based on the Transtheoretical Stages of Change Model)
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The primary decision-making outcome is change in intent to discuss palliative care based on the Transtheoretical Stages of Change Model (i.e., pre-contemplation, contemplation, preparation, action, and maintenance).
|
Within six months after patient enrolls in study, June 2017.
|
|
Intent to Discuss Hospice Care (Based on the Transtheoretical Stages of Change Model)
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The primary decision-making outcome is change in intent to discuss hospice care based on the Transtheoretical Stages of Change Model (i.e., pre-contemplation, contemplation, preparation, action, and maintenance).
|
Within six months after patient enrolls in study, June 2017.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life at the End of Life
Time Frame: Within six months after patient enrolls in study, June 2017.
|
This will be assessed by using the McGill QOL Questionnaire, Part A, which measures overall quality of life in a 48 hour period: "Considering all parts of my life - physical, emotional, social, spiritual, and financial - over the past two (2) days the quality of my life has been: 0-10," with 0=very bad and 10=excellent.
|
Within six months after patient enrolls in study, June 2017.
|
|
Health Care Utilization: Emergency Room
Time Frame: Within six months after patient enrolls in study, June 2017.
|
Health care utilization will be measured mean number of ER visits for the intervention and control groups.
|
Within six months after patient enrolls in study, June 2017.
|
|
Number of Patients Who Died
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The principal investigator or research staff will attempt to determine the date and location of death for patients who have died while enrolled in the study by reviewing the patient's electronic health record.
|
Within six months after patient enrolls in study, June 2017.
|
|
Utilization of Advance Care Planning and End-of-life Care
Time Frame: Within six months after patient enrolls in study, June 2017.
|
The number of participants who have documentation of advance care planning, palliative care clinic visits, and/or hospice enrollment.
|
Within six months after patient enrolls in study, June 2017.
|
|
Health Care Utilization: Mean Number of Hospitalizations in Six Months by Group
Time Frame: Within six months after patient enrolls in study, June 2017.
|
Health care utilization will be measured mean number of hospitalizations by group, obtained by chart abstraction.
|
Within six months after patient enrolls in study, June 2017.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Ethan Halm, MD, Chair, Department of General Internal Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Skin Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Neoplasms
- Breast Neoplasms
- Lung Neoplasms
- Death
- Colonic Neoplasms
Other Study ID Numbers
- STU 032013-051
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Cancer | Breast Carcinoma | Malignant Neoplasm of Breast | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Massachusetts General HospitalMassachusetts Institute of TechnologyNot yet recruitingBreast Cancer | Breast Asymmetry | Breast Abnormalities | Breast LesionUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastJapan
-
GlaxoSmithKlineCompletedMetastatic Breast Cancer | Neoplasms, BreastUnited States
Clinical Trials on Educational DVD
-
Thomas Jefferson UniversityMain Line Health; The Reading Hospital and Medical CenterCompletedOvarian CystsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast, Cervical or Colorectal Cancer Screening NeededUnited States
-
University of Alabama at BirminghamCompletedPain ManagementUnited States
-
Northwestern UniversityAgency for Healthcare Research and Quality (AHRQ)TerminatedColorectal CancerUnited States
-
University of CincinnatiFoundation for Informed Medical Decision MakingCompletedCoronary Artery DiseaseUnited States
-
Temple UniversityUniversity of Michigan; National Institute of Dental and Craniofacial Research... and other collaboratorsCompletedDental Caries | Oral Hygiene | Oral Health | Dental HealthUnited States
-
Queen's UniversityCompleted
-
M.D. Anderson Cancer CenterPatient-Centered Outcomes Research InstituteCompletedSmoking Cessation | Lung Cancer | Tobacco Use CessationUnited States
-
The Miriam HospitalNational Institute of Mental Health (NIMH); Brown University; University of Rochester and other collaboratorsCompletedHIV Infections | Sexually Transmitted Diseases | HIVUnited States
-
Cooper Green Mercy HospitalUniversity of Alabama at BirminghamUnknownHypertensionUnited States